PNV 6.62% $2.54 polynovo limited

I also like to consider market reach. Although hesitant to use...

  1. 1,694 Posts.
    lightbulb Created with Sketch. 190
    I also like to consider market reach. Although hesitant to use Dominos as a comparison (but think store expansion), for PNV it is obviously hospitals. Now naturally unlike Dominos, there could be no sales happening at some hospitals. However, assuming the product does what we know it does and is effective and price competitive (again known facts)...
    2019 - 60, 2020- 249, 2021-355, 2022-470, and 2023-638, 2024 ~??

    IF the increasing costs and delay in achieving positive cash flow was due to mostly to R&D (not that this is a negative factor as some medical companies are still developing their tech), but PNV is expanding its sales capacity.

    The sales model with the product is proven. It's simply about getting it in front of 'eyes' (no cross promoting TA007!). Spend up PNV - spend up big getting it in front of as many surgeons all over the world! ASAP!!
 
watchlist Created with Sketch. Add PNV (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.